Drugs / KX-826
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT05218642 | Jan 2022 → Feb 2023 | baldness, male pattern | Suzhou Kintor Pharmaceutical Inc | Completed | No outcome recorded |
| Phase 2 | NCT06409650 | Nov 2021 → Nov 2022 | alopecia | Suzhou Koshine Biomedica, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05940506 | Sep 2020 → Jul 2021 | androgenetic alopecia | Suzhou Kintor Pharmaceutical Inc | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06622824 | Oct 2024 → Oct 2027 expected | androgenetic alopecia | Suzhou Kintor Pharmaceutical Inc | Not yet recruiting | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT06126965 | Dec 2021 → May 2024 | androgenetic alopecia | Suzhou Kintor Pharmaceutical Inc | Unknown | Met primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-03-18 | Suzhou Kintor Pharmaceutical Inc, | Results KX-826酊1.0%治疗中国成年男性雄激素脱发关键性临床试验III期阶段达到主要终点 kintor.com.cn ↗
北京时间2026年3月18日，开拓药业（股票代码：9939.HK），宣布其自主研发、潜在同类首创的 KX-826 酊 1.0% 治疗脱发的关键性临床试验III期阶段已获得顶线数据。 |
| 2025-07-24 | Suzhou Kintor Pharmaceutical Inc, | Results KX-826酊1.0%治疗中国成年男性雄激素脱发关键性临床试验II期阶段达到主要终点 kintor.com.cn ↗
北京时间2025年7月24日，开拓药业（股票代码：9939.HK），宣布 其自主研发、潜在同类首创的KX-826酊1.0%治疗脱发的关键性临床试验II期阶段已获得顶线数据。 |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-03-18 | Suzhou Kintor Pharmaceutical Inc, | KX-826酊1.0%治疗中国成年男性雄激素脱发关键性临床试验III期阶段达到主要终点 kintor.com.cn ↗ |
| 2025-07-24 | Suzhou Kintor Pharmaceutical Inc, | KX-826酊1.0%治疗中国成年男性雄激素脱发关键性临床试验II期阶段达到主要终点 kintor.com.cn ↗ |
| 2024-07-01 | Suzhou Kintor Pharmaceutical Inc, | KX-826 雄激素受体拮抗剂 kintor.com.cn ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KX-826 | “KX-826 is a new investigational androgen receptor (AR) antagonist for the treatment of male pattern hair loss (androgenetic alopecia).” NCT05218642 ↗ |
| Action | Inhibit | “androgen receptor (AR) antagonist” NCT05218642 ↗ |
| Route | Topical | “2.5mg of the investigational drug to be applied topically to scalp twice daily for 24 weeks” NCT05218642 ↗ |
| Target | AR | “androgen receptor (AR) antagonist” NCT06409650 ↗ |